SELDI-TOF蛋白质谱分析技术在泌尿外科肿瘤诊断中的应用
摘要
近年来,针对肿瘤的研究已经不仅仅局限于基因组的研究,而是已经大大扩展到了蛋白质表达分析的层面。蛋白质组学以及相关的技术特别是SELDI技术在泌尿外科方面的应用也仅仅是最近几年间的新进展,仍然有广阔的前景等待开拓。该技术及已经被证明是一种高度敏感以及高通量的质谱分析技术,并且在肿瘤标记物的探索方面已经取得了可喜的成果。本文将介绍SELDI-TOF技术在泌尿外科肿瘤诊断方面的最新应用进展。
出处
《国际泌尿系统杂志》
2007年第4期459-462,共4页
International Journal of Urology and Nephrology
参考文献20
-
1Adam BL, Qu Y, Davis JW, et al. Serum protein fingerprinting coupled with a pattern - matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res, 2002,62 (13) :3609 -3614.
-
2Ornstein DK,Rayford W,Fusaro VA,et al. Serum proteomic profiling can discriminate prostate cancer from benign prostates in men with total prostate specific antigen levels between 2.5 and 15.0 ng/ml. J Urol,2004,172 : 1302 - 1305.
-
3Ou Y,Adam BL,Yasui Y,et al. Boosted decision tree analysis of surface- enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. Clin Chem,2002,48(10) :1835 - 1843.
-
4Hlavaty JJ, Partin AW, Kusinitz F,et al. Mass spectroscopy as a discovery tool for identifying serum markers for prostate cancer.Clin Chem,2001,47 : 1924 - 1926.
-
5Petricoin EF, Omstein DK, Paweletz CP, et al. Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst, 2002,94 (20) :1576 - 1578.
-
6Hlavaty JJ, Partin AW, Shue MJ, et al. Identification and preliminary clinical evaluation of a 50.8 - kDa serum marker for prostate cancer. Urology,2003,61(6) : 1261 - 1265.
-
7Malik G, Ward MD, Gupta SK, et al. Serum levels of an isoform of apolipoprotein A - Ⅱ as a potential marker for prostate cancer. Clin Cancer Res,2005,11 : 1073 - 1085.
-
8Le L, Chi K, Tyldesley S, et al. Identification of serum amyloid A as a biomarker to distinguish prostate cancer patients with bone lesions. Clin Chem,2005,51:695 -707.
-
9Won Y, Song HJ, Kang TW, et al. Pattern analysis of serum proteome distinguishes renal cell carcinoma from other urologic diseases and healthy persons. Protcomics ,2003,3:2310 - 2316.
-
10Hara T, Honda K, Ono M, et al. Identification of 2 serum biomarkers of renal cell carcinoma by surface enhanced laser desorption/ionization mass spectrometry. J Urol,2005 ,174 :1213 - 1217.
二级参考文献13
-
1Fields S. Proteomics in genomeland. Science, 2001,291:1221-1224.
-
2Pandey A,Mann M. Proteomics to study genes and genomes. Nature,2000, 405:837-846.
-
3Sarto C, Frutiger S, Cappellano F, et al. Modified expression of plasma glutathione peroxidase and manganese superoxide dismutase in human renal cell carcinoma. Electrophoresis,1999, 20 :3458-3466.
-
4Balabanov S, Zimmermann U, Protzel C, et al. Tumour-related enzyme alterations in the clear cell type of human renal cell carcinoma identified by two-dimensional gel electrophoresis. Eur J Biochem,2001, 268:5977-5980.
-
5Klade CS, Voss T, Krystek E, et al. Identification of tumor antigens in renal cell carcinoma by serological proteome analysis. Proteomics, 2001, 1:890-898.
-
6Ferrari L, Seraglia R, Rossi CR, et al. Protein profiles in sera of patients with malignant cutaneous melanoma. Rapid Commun Mass Spectrom, 2000,14: 1149-1154.
-
7Merchant M, Weinberger SR. Recent advancements in surface-enhanced laser desorption/ionization-time of flight-mass spectrometry. Electrophoresis,2000, 21:1164-1177.
-
8Bryumor W, Robert S, Shannon B, et al. Detection of early-stage cancer by serum protein analysis. Am Laboratory, 2001,6:32-36.
-
9von Eggeling F, Davies H, Lomas L, et al. Tissue-specific microdissection coupled with ProteinChip array technologies: applications in cancer research. Biotechniques, 2000, 29: 1066-1070.
-
10Wright GL, Cazares LH, Leung SM,et al. ProteinChip surface enhanced laser desorption/ionization (SELDI) mass spectrometry: a novel protein biochip technology for detection of biomarker in complex protein mixtures. Prostate Cancer and Prostatic Disease, 20
共引文献21
-
1范青锋,管娜,丁洁.尿蛋白质组学在肾脏疾病生物标志物鉴定中的作用[J].肾脏病与透析肾移植杂志,2005,14(1):71-73. 被引量:4
-
2王斌,米振国.蛋白质芯片SELDI-TOF-MS技术与泌尿系肿瘤研究[J].国外医学(泌尿系统分册),2005,25(3):297-300.
-
3赖梅生,范瑞强,吴元胜.系统性红斑狼疮中医研究展望[J].四川中医,2006,24(2):43-45. 被引量:1
-
4张锐强,谢静,刘振元,张玉石,李汉忠,邓碧萍,李宁,王彭.血清蛋白质指纹图谱模型在肾癌诊断中的应用[J].中华泌尿外科杂志,2006,27(8):527-529. 被引量:8
-
5黄盛松,吴登龙.SELDI-TOF-MS蛋白质芯片技术早期诊断前列腺癌[J].国际泌尿系统杂志,2006,26(5):606-609.
-
6章晓鹰(综述),何立群(审校),张悦(审校).尿液蛋白质组学在肾脏病研究中的应用[J].国际检验医学杂志,2007,28(1):70-71.
-
7吴腾燕,仇小强.蛋白质芯片技术在筛选疾病标志物中应用[J].中国公共卫生,2007,23(12):1529-1531. 被引量:2
-
8刘茶珍,朱佩云,施民新,刘继斌,廖萍,项翠琴,张一心,王文静.应用IMAC3蛋白芯片分析食管鳞癌患者血清蛋白质谱的变化[J].癌症,2008,27(3):272-278. 被引量:20
-
9徐罡,项翠琴,陆晔,康晓楠,王文静,廖萍,丁强,张元芳.应用SELDI—TOF—MS技术联合CT鉴别肾脏良恶性占位[J].中华医学杂志,2008,88(12):858-860. 被引量:4
-
10龙江,狄扬,金忱,虞先浚,刘维薇,陈宇明,傅德良,倪泉兴.血清蛋白质指纹图谱预测模型在胰腺癌诊断中的应用研究[J].中华医学杂志,2008,88(22):1533-1536. 被引量:2
-
1高红军,赵晓航.SELDI-TOF MS技术与小分子肿瘤相关蛋白的鉴定[J].中国肿瘤,2009,18(8):643-647.
-
2冯丹,蔡清萍.乳腺癌微创治疗研究进展[J].中国肿瘤,2008,17(12):1040-1043. 被引量:4
-
3刘枋,林志强,陈慧菁,林艳,林丽婷,陈强,叶韵斌.血清Cyfra21-1和SELDI技术联合检测肺鳞癌的临床意义[J].肿瘤防治研究,2011,38(5):539-541. 被引量:2
-
4邓勇军,杨鸿生.ras基因、环境因素在肺癌中的作用研究进展[J].国外医学(肿瘤学分册),2004,31(3):205-208. 被引量:1
-
5宋森涛,朱梁,谢渭芬.蛋白质芯片质谱仪在肿瘤标志物研究中的应用[J].国外医学(肿瘤学分册),2003,30(6):415-417.
-
6张菊新,罗穗豫,肖乐义,张子宽,吕文秀.卵巢癌临床症状和早期诊断技术研究进展[J].中国肿瘤,2005,14(10):671-674. 被引量:2
-
7陆海波,赵长宏,马玉彦,鲁海玲,白玉贤.血清蛋白质指纹图谱诊断早期胃癌临床意义[J].现代生物医学进展,2006,6(8):12-14. 被引量:3
-
8吉利娜,黄金,张永亮,陈妍,裴毅.用SELDI技术指导化疗和吉非替尼序贯治疗非小细胞肺癌的前瞻性研究[J].中国现代医生,2011,49(1):17-18.
-
9王立国,王瑞宽.结肠癌致急性完全性肠梗阻19例[J].中国肛肠病杂志,2007,27(2):39-39.
-
10布立民,邹江,张国梁,徐峰,陈立.DNA甲基转移酶1和DNA甲基转移酶3B基因单核苷酸多态性与结直肠癌易感性的关系[J].中华实验外科杂志,2014,31(10):2341-2341. 被引量:1